7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 
      
    		                                                              
      cash flows from operating activities
    		                                                              
      net income
    		5,787,000,000 4,429,000,000 5,085,000,000 3,744,000,000 3,161,000,000 5,461,000,000 4,767,000,000  4,750,000,000 -5,972,000,000 2,825,000,000        3,186,000,000 -2,091,000,000 2,944,000,000 3,010,000,000 3,219,000,000 2,363,000,000 1,908,000,000 2,644,000,000 2,862,000,000 1,778,000,000 1,958,000,000 1,716,000,000 741,000,000 -1,038,000,000 -51,000,000 1,951,000,000 1,556,000,000 -587,000,000 2,189,000,000 1,209,000,000 1,130,000,000 982,000,000 1,831,000,000 688,000,000 958,000,000 7,327,000,000 843,000,000 2,033,000,000 1,731,000,000 815,000,000 1,151,000,000 1,543,000,000 1,724,000,000 2,054,000,000 1,071,000,000 -500,000,000 371,600,000 780,200,000 330,200,000 805,000,000  589,000,000 435,000,000 291,000,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                              
      amortization
    		622,000,000 601,000,000 597,000,000 675,000,000 633,000,000 614,000,000 473,000,000 462,000,000 562,000,000 477,000,000 543,000,000 462,000,000 460,000,000 464,000,000 699,000,000 405,000,000 360,000,000 337,000,000 534,000,000                                            
      depreciation
    		532,000,000 518,000,000 502,000,000 522,000,000 553,000,000 518,000,000 511,000,000 502,000,000 452,000,000 426,000,000 448,000,000 430,000,000 499,000,000 474,000,000 421,000,000 430,000,000 399,000,000 353,000,000 396,000,000                                            
      income from investments in equity securities
    		-374,000,000 -99,000,000 -90,000,000  31,000,000 -57,000,000 -143,000,000         -405,000,000                                               
      charges for research and development asset acquisitions
    		                                                              
      deferred income taxes
    		-212,000,000 -448,000,000 -186,000,000 -616,000,000 -401,000,000 -181,000,000 -51,000,000 -931,000,000 -336,000,000 -355,000,000 -277,000,000 -307,000,000 -661,000,000 -262,000,000 -338,000,000 159,000,000 -1,000,000 39,000,000 -10,000,000 -715,000,000 -75,000,000 40,000,000 82,000,000 -170,000,000 -237,000,000 -343,000,000 194,000,000 -118,000,000 -133,000,000 -228,000,000 -30,000,000 -2,020,000,000 -329,000,000 -218,000,000 -54,000,000 -1,456,000,000 55,000,000 -50,000,000 -70,000,000 82,000,000 -463,000,000 -204,000,000 -179,000,000 -827,000,000 -527,000,000 -942,000,000 -304,000,000 202,000,000 -213,000,000 -563,000,000 -133,000,000 -627,000,000 -214,000,000 -349,200,000 -423,900,000 -471,100,000 152,200,000      
      share-based compensation
    		204,000,000 216,000,000 195,000,000 187,000,000 195,000,000 203,000,000 176,000,000 167,000,000 164,000,000 169,000,000 145,000,000 145,000,000 139,000,000 137,000,000 120,000,000 119,000,000 117,000,000 123,000,000 120,000,000 121,000,000 125,000,000 121,000,000 108,000,000 111,000,000 102,000,000 111,000,000 93,000,000 87,000,000 91,000,000 90,000,000 80,000,000 80,000,000 76,000,000 82,000,000 74,000,000 75,000,000 77,000,000 80,000,000 68,000,000 78,000,000 75,000,000 83,000,000 63,000,000 69,000,000 75,000,000 78,000,000 56,000,000 66,000,000 68,000,000 82,000,000 87,000,000 107,000,000 93,000,000 109,500,000 125,300,000 141,800,000 132,400,000      
      other
    		-51,000,000 335,000,000 109,000,000 -101,000,000 437,000,000 91,000,000 83,000,000 449,000,000 -99,000,000 202,000,000 -197,000,000 132,000,000 393,000,000 633,000,000 143,000,000 306,000,000 1,025,000,000 -195,000,000 -331,000,000 396,000,000 -243,000,000 -345,000,000 143,000,000 -35,000,000 105,000,000 -6,000,000 120,000,000 393,000,000 156,000,000 379,000,000 50,000,000 300,000,000 -94,000,000 91,000,000 -28,000,000 66,000,000 50,000,000 100,000,000 97,000,000 60,000,000 120,000,000 26,000,000 551,000,000 -45,000,000 142,000,000 -77,000,000 -115,000,000 112,000,000 -85,000,000 530,000,000 249,000,000 -234,000,000 -222,000,000 -66,600,000 6,600,000 249,000,000 188,000,000 2,000,000     
      net changes in assets and liabilities
    		1,314,000,000 -2,259,000,000 -3,712,000,000  2,582,000,000 -1,012,000,000 -3,382,000,000  2,177,000,000 -1,636,000,000 -2,890,000,000  263,000,000 -1,399,000,000 -1,299,000,000  -139,000,000 -1,551,000,000 -2,104,000,000  -1,445,000,000 -527,000,000 -3,666,000,000  -91,000,000 -443,000,000 -2,935,000,000  -760,000,000 199,000,000 -1,473,000,000  -2,922,000,000 198,000,000 -2,535,000,000  -564,000,000 -1,563,000,000 -875,000,000  223,000,000 -392,000,000 -618,000,000  2,068,000,000 -415,000,000 -703,000,000  1,315,000,000  821,000,000 -418,000,000 -1,067,000,000  787,100,000 1,058,500,000 -1,064,000,000      
      net cash from operating activities
    		7,822,000,000 3,293,000,000 2,500,000,000 3,450,000,000 9,291,000,000 5,637,000,000 3,090,000,000  7,717,000,000 3,704,000,000 1,339,000,000     -64,000,000 0 -740,000,000 1,791,000,000 4,006,000,000 2,173,000,000 3,367,000,000 707,000,000 4,794,000,000 4,226,000,000 3,084,000,000 1,336,000,000 3,592,000,000 2,793,000,000 3,382,000,000 1,155,000,000 4,015,000,000 -1,171,000,000 3,317,000,000 286,000,000 3,632,000,000 2,971,000,000 1,615,000,000 2,158,000,000 4,247,000,000 3,305,000,000 2,585,000,000 2,284,000,000 -1,164,000,000 4,348,000,000 2,315,000,000 2,361,000,000 3,026,000,000 3,949,000,000 3,233,000,000 4,577,000,000 2,852,000,000 1,721,000,000 3,539,100,000 2,591,900,000 3,324,900,000 1,366,100,000 556,000,000 599,000,000 1,191,000,000   
      cash flows from investing activities
    		                                                              
      capital expenditures
    		-987,000,000 -764,000,000 -1,328,000,000 -937,000,000 -783,000,000 -791,000,000 -861,000,000 -989,000,000 -902,000,000 -965,000,000 -1,007,000,000 -1,149,000,000 -1,126,000,000 -1,129,000,000 -984,000,000 -1,208,000,000 -1,172,000,000 -934,000,000 -1,134,000,000 -1,514,000,000 -1,516,000,000 -668,000,000 -986,000,000 -1,137,000,000 -959,000,000 -782,000,000 -595,000,000 -929,000,000 -653,000,000 -583,000,000 -450,000,000 -715,000,000 -441,000,000 -393,000,000 -339,000,000 -551,000,000 -409,000,000 -375,000,000 -279,000,000 -493,000,000 -316,000,000 -271,000,000 -203,000,000 -490,000,000 -320,000,000 -302,000,000 -205,000,000 -429,000,000 -355,000,000 -603,000,000 -431,000,000 -365,000,000 -324,000,000 -660,300,000 -337,900,000 -337,000,000 -342,800,000 -161,000,000  -172,000,000 -195,000,000 -175,000,000 
      free cash flows
    		6,835,000,000 2,529,000,000 1,172,000,000 2,513,000,000 8,508,000,000 4,846,000,000 2,229,000,000  6,815,000,000 2,739,000,000 332,000,000     -1,272,000,000 -1,172,000,000 -1,674,000,000 657,000,000 2,492,000,000 657,000,000 2,699,000,000 -279,000,000 3,657,000,000 3,267,000,000 2,302,000,000 741,000,000 2,663,000,000 2,140,000,000 2,799,000,000 705,000,000 3,300,000,000 -1,612,000,000 2,924,000,000 -53,000,000 3,081,000,000 2,562,000,000 1,240,000,000 1,879,000,000 3,754,000,000 2,989,000,000 2,314,000,000 2,081,000,000 -1,654,000,000 4,028,000,000 2,013,000,000 2,156,000,000 2,597,000,000 3,594,000,000 2,630,000,000 4,146,000,000 2,487,000,000 1,397,000,000 2,878,800,000 2,254,000,000 2,987,900,000 1,023,300,000 395,000,000  1,019,000,000   
      purchases of securities and other investments
    		0 -612,000,000 -595,000,000 -455,000,000 0 -49,000,000 -15,000,000 -251,000,000 -117,000,000 -25,000,000 -562,000,000 -494,000,000 -5,000,000 -333,000,000 -372,000,000 0 0 0 -1,000,000 -17,000,000 -1,000,000 -28,000,000 -49,000,000 -822,000,000 -570,000,000 -836,000,000 -974,000,000 -1,095,000,000 -1,651,000,000 -3,922,000,000 -1,326,000,000 -2,342,000,000 -2,117,000,000 -3,351,000,000 -2,929,000,000 -5,567,000,000 -3,729,000,000 -3,988,000,000 -2,367,000,000 -4,256,000,000 -3,804,000,000 -3,582,000,000 -5,039,000,000 -8,713,000,000 -3,851,000,000 -5,555,000,000 -6,825,000,000 -4,914,000,000 -4,259,000,000 -2,639,000,000 -1,620,000,000 -1,684,000,000 -1,382,000,000 -1,370,900,000 -1,590,900,000 -1,302,500,000 -2,932,700,000      
      proceeds from sales of securities and other investments
    		575,000,000 601,000,000 456,000,000 7,000,000 50,000,000 60,000,000 260,000,000 169,000,000 704,000,000 285,000,000 500,000,000 12,000,000 335,000,000 373,000,000 1,000,000 529,000,000 111,000,000 0 386,000,000 918,000,000 2,000,000 76,000,000 1,816,000,000 1,163,000,000 2,524,000,000 3,036,000,000 1,899,000,000 4,009,000,000 3,840,000,000 5,555,000,000 1,848,000,000 3,131,000,000 3,170,000,000 2,544,000,000 6,819,000,000 3,053,000,000 3,912,000,000 2,768,000,000 4,620,000,000 3,882,000,000 3,903,000,000 6,341,000,000 6,287,000,000 3,307,000,000 3,705,000,000 5,470,000,000 2,632,000,000 6,475,000,000 2,628,000,000 1,409,000,000 1,850,000,000 1,366,000,000 1,524,000,000 834,700,000 2,026,700,000 1,426,900,000 272,700,000      
      acquisition of eyebiotech limited, net of cash acquired
    		   0                                                           
      acquisition of elanco animal health incorporated aqua business
    		   -2,000,000                                                           
      acquisition of harpoon therapeutics, inc., net of cash acquired
    		   0 0 0 -746,000,000                                                        
      acquisition of mk-1045 (formerly cn201) from curon pharmaceutical
    		                                                              
      net cash from investing activities
    		-283,000,000 -770,000,000 -1,487,000,000 -1,444,000,000 -3,845,000,000 -1,069,000,000 -1,376,000,000  -334,000,000 -11,443,000,000 -2,359,000,000     0 0 604,000,000 -738,000,000 -4,778,000,000 -2,155,000,000 -882,000,000 -1,628,000,000 -763,000,000 191,000,000 -2,425,000,000 368,000,000 2,178,000,000 1,660,000,000 673,000,000 -197,000,000 -58,000,000 671,000,000 -1,127,000,000 3,193,000,000 -2,563,000,000 -890,000,000 -1,498,000,000 1,741,000,000 -617,000,000 -61,000,000 2,525,000,000 -6,605,000,000 7,204,000,000 -3,722,000,000 -49,000,000 -3,807,000,000 1,177,000,000 -2,037,000,000 -1,684,000,000 -263,000,000 -1,048,000,000 105,000,000 -1,007,500,000 194,800,000   -861,000,000     
      cash flows from financing activities
    		                                                              
      net change in short-term borrowings
    		15,000,000               -3,000,000 0 -4,771,000,000 788,000,000 2,860,000,000 -2,278,000,000 -1,616,000,000 3,583,000,000 182,000,000 -360,000,000 603,000,000 -4,135,000,000 2,830,000,000 225,000,000 2,070,000,000 -1,000,000 -1,988,000,000 1,986,000,000 -3,808,000,000 3,784,000,000  918,000,000   -14,000,000 3,000,000 -3,706,000,000 2,177,000,000 -3,537,000,000 4,963,000,000 -5,035,000,000 3,149,000,000 -310,000,000 -1,551,000,000 -280,000,000 -40,000,000 1,593,000,000 -197,000,000 -1,483,000,000 -84,700,000 -962,700,000 2,620,400,000 -2,000,000  -167,000,000 -4,000,000 -36,000,000 
      proceeds from issuance of debt
    		   0 -1,000,000   0 -7,000,000           0 -26,000,000   0 0 0 4,958,000,000         1,071,000,000 0   0 -2,000,000 -1,000,000 7,941,000,000 3,145,000,000 0   0 0              
      payments on debt
    		-1,000,000 0 -2,500,000,000 -539,000,000 0 0 -751,000,000 -3,000,000 -1,000,000 -1,750,000,000 -1,000,000 -1,000,000 -1,000,000,000 0 -1,250,000,000 -1,166,000,000 0 0 -1,153,000,000 -3,000,000 -2,000,000 -1,000,000 -1,951,000,000     -1,280,000,000 1,000,000 -2,005,000,000 -1,003,000,000 -802,000,000 0 -1,000,000 -300,000,000 0 -35,000,000 -1,500,000,000 -851,000,000 -1,000,000 0 -3,000,000 -2,902,000,000 -6,610,000,000 -2,000,000 -2,000,000 -3,000,000 -1,260,000,000 0 -270,000,000 -12,000,000 -1,261,000,000 -4,000,000 -651,700,000 -63,200,000 -3,800,000 -622,300,000      
      dividends paid to stockholders
    		-2,031,000,000 -2,077,000,000 -2,050,000,000 -1,951,000,000 -1,953,000,000 -1,986,000,000 -1,950,000,000 -1,852,000,000 -1,855,000,000 -1,885,000,000 -1,853,000,000 -1,750,000,000 -1,747,000,000 -1,770,000,000 -1,745,000,000 -1,643,000,000 -1,649,000,000 -1,673,000,000 -1,645,000,000 -1,542,000,000 -1,545,000,000 -1,577,000,000 -1,551,000,000 -1,405,000,000 -1,394,000,000 -1,468,000,000 -1,428,000,000 -1,277,000,000 -1,285,000,000 -1,311,000,000 -1,299,000,000 -1,283,000,000 -1,283,000,000 -1,307,000,000 -1,294,000,000 -1,271,000,000 -1,274,000,000 -1,300,000,000 -1,279,000,000 -1,263,000,000 -1,272,000,000 -1,302,000,000 -1,280,000,000 -1,259,000,000 -1,282,000,000 -1,339,000,000 -1,290,000,000 -1,260,000,000 -1,259,000,000 -1,165,000,000 -1,175,000,000 -1,176,000,000 -1,175,000,000 -1,174,800,000 -1,181,300,000 -1,189,300,000 -1,188,600,000      
      purchases of treasury stock
    		-1,323,000,000 -1,345,000,000 -1,164,000,000 -489,000,000 -444,000,000 -251,000,000 -122,000,000 -393,000,000 -466,000,000 -338,000,000 -149,000,000     -18,000,000 -583,000,000   0 0 0 -1,281,000,000 -1,050,000,000 -1,405,000,000 -1,235,000,000 -1,090,000,000 -5,933,000,000 -996,000,000 -1,596,000,000 -566,000,000 -1,702,000,000 -159,000,000 -1,134,000,000 -1,019,000,000 -1,016,000,000 -845,000,000 -660,000,000 -913,000,000 -1,181,000,000 -1,281,000,000 -709,000,000 -1,015,000,000 -1,620,000,000 -2,670,000,000 -2,246,000,000 -1,167,000,000 -196,000,000 -215,000,000 -562,000,000 -1,045,000,000   300,000 -296,100,000        
      proceeds from exercise of stock options
    		14,000,000 12,000,000 19,000,000 12,000,000 5,000,000 73,000,000 87,000,000 6,000,000 7,000,000 82,000,000 30,000,000 265,000,000 10,000,000 97,000,000 12,000,000 134,000,000 17,000,000 42,000,000 9,000,000 21,000,000 28,000,000 14,000,000 26,000,000 17,000,000 40,000,000 131,000,000 173,000,000 130,000,000 162,000,000 69,000,000 230,000,000 18,000,000 73,000,000 95,000,000 313,000,000 149,000,000 409,000,000 179,000,000 202,000,000 51,000,000 57,000,000 135,000,000 242,000,000 179,000,000 247,000,000 203,000,000 931,000,000 401,000,000 168,000,000 127,000,000 32,000,000 125,000,000 37,000,000 50,100,000 75,700,000 41,900,000 195,300,000      
      net cash from financing activities
    		2,638,000,000 -3,556,000,000 -5,755,000,000 -3,009,000,000 -2,425,000,000 1,216,000,000 -2,814,000,000  -4,269,000,000 3,758,000,000 -2,054,000,000     0 0 1,594,000,000 -2,098,000,000 1,372,000,000 -3,851,000,000 1,137,000,000 -1,490,000,000 -2,011,000,000 -3,152,000,000 -2,084,000,000 -1,614,000,000 -5,566,000,000 -1,905,000,000 -2,967,000,000 -2,722,000,000 -5,785,000,000 536,000,000 -6,218,000,000 1,461,000,000 -1,977,000,000 -835,000,000 -3,381,000,000 -2,851,000,000 -2,407,000,000 -2,533,000,000 -5,485,000,000 5,155,000,000 -9,643,000,000 1,279,000,000 -8,369,000,000 1,620,000,000 -2,624,000,000 -2,915,000,000 -2,231,000,000 -2,244,000,000 -1,257,000,000 -1,172,000,000 -1,294,900,000 -1,625,000,000   -181,000,000   -465,000,000 -184,000,000 
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		10,000,000 374,000,000 156,000,000 -367,000,000 294,000,000 -82,000,000 -138,000,000 186,000,000 -157,000,000 -93,000,000 87,000,000 366,000,000 -412,000,000 -309,000,000 -55,000,000 -68,000,000 -46,000,000 78,000,000 -97,000,000 164,000,000 87,000,000 65,000,000 -63,000,000 43,000,000 -54,000,000 8,000,000 20,000,000 -65,000,000 -32,000,000 -262,000,000 154,000,000                                
      net increase in cash, cash equivalents and restricted cash
    		10,187,000,000   -1,370,000,000 3,315,000,000   -1,760,000,000 2,957,000,000 -4,074,000,000 -2,987,000,000 1,494,000,000 1,526,000,000 1,139,000,000 447,000,000 -1,879,000,000 1,416,000,000     3,687,000,000 -2,474,000,000 2,063,000,000   110,000,000 139,000,000 2,516,000,000 826,000,000 -1,610,000,000                                
      cash, cash equivalents and restricted cash at beginning of year
    		0 0 13,318,000,000 0 0 0 6,909,000,000 0 0 0 12,773,000,000 0 0 0 8,167,000,000 0 0 -12,000,000 8,165,000,000 0 0 0 9,934,000,000 0 0 0 7,967,000,000 0 0 0 6,096,000,000                                
      cash, cash equivalents and restricted cash at end of period
    		10,187,000,000 -659,000,000 8,732,000,000  3,315,000,000 5,702,000,000 5,671,000,000  2,957,000,000 -4,074,000,000 9,786,000,000  1,526,000,000 1,139,000,000 8,614,000,000  1,416,000,000 1,607,000,000 7,023,000,000  -3,746,000,000 3,687,000,000 7,460,000,000  1,211,000,000 -1,417,000,000 8,077,000,000  2,516,000,000 826,000,000 4,486,000,000                                
      inventories
    		                                                         -239,000,000 161,000,000 -23,000,000 26,000,000 -138,000,000 
      property, plant and equipment
    		                                                              
      product rights - clynav
    		                                                              
      other product rights
    		                                                              
      deferred tax asset
    		                                                              
      other assets and liabilities
    		                                                              
      total identifiable net assets
    		                                                              
      goodwill
    		                                                              
      consideration transferred
    		                                                              
      charge for research and development asset acquisition
    		                                                              
      alliance revenue - lynparza
    		 58,000,000 312,000,000   25,000,000 292,000,000  -11,000,000 35,000,000 275,000,000                                                    
      alliance revenue - koselugo
    		 -1,000,000 44,000,000   -1,000,000 38,000,000  1,000,000 2,000,000 23,000,000                                                    
      total alliance revenue
    		 57,000,000 356,000,000   24,000,000 330,000,000  -10,000,000 37,000,000 298,000,000                                                    
      cost of sales
    		 3,000,000 83,000,000   0 82,000,000  4,000,000 8,000,000 70,000,000                                                    
      selling, general and administrative
    		 8,000,000 32,000,000   4,000,000 39,000,000  -7,000,000 4,000,000 47,000,000                                                    
      research and development
    		 4,000,000 12,000,000   -2,000,000 20,000,000  1,000,000 1,000,000 21,000,000                                                    
      receivables from astrazeneca included in other current assets
    		  358,000,000    334,000,000    303,000,000                                                    
      payables to astrazeneca included in accrued and other current liabilities
    		  15,000,000    617,000,000    21,000,000                                                    
      net decrease in cash, cash equivalents and restricted cash
    		  -4,586,000,000    -1,238,000,000            -1,142,000,000                                            
      intangible asset impairment charges
    		       779,000,000    839,000,000 887,000,000       1,683,000,000 15,000,000   176,000,000 612,000,000 148,000,000 104,000,000     270,000,000 245,000,000 51,000,000 80,000,000 3,376,000,000 5,000,000 290,000,000 277,000,000 82,000,000 7,000,000 59,000,000 14,000,000 13,000,000 549,000,000   171,000,000 0 244,000,000 22,000,000            
      (income) income from investments in equity securities
    		       -100,000,000 34,000,000 176,000,000 -450,000,000                                                    
      charges for certain research and development asset acquisitions
    		                                                              
      net changes in assets and liabilities:
    		                                                              
      accounts receivable
    		                                                         -292,000,000 223,000,000 275,000,000 -24,000,000 -383,000,000 
      trade accounts payable
    		                                                              
      accrued and other current liabilities
    		                                                              
      income taxes payable
    		                                                              
      noncurrent liabilities
    		                                                              
      proceeds from sale of seagen inc. common stock
    		                                                              
      acquisition of mk-1045 from curon pharmaceutical
    		                                                              
      acquisition of prometheus biosciences, inc., net of cash acquired
    		       0 0                                                      
      acquisition of imago biosciences inc., net of cash acquired
    		                                                              
      cash, cash equivalents and restricted cash at end of year
    		                                                              
      charge for the acquisition of eyebiotech limited
    		                                                              
      charge for the acquisition of mk-1045 (formerly cn201) from curon pharmaceutical
    		                                                              
      charge for the acquisition of harpoon therapeutics, inc.
    		    0 0 656,000,000                                                        
      charge for the acquisition of prometheus biosciences, inc.
    		       0 0                                                      
      charge for the acquisition of imago biosciences, inc.
    		       0 0 0 1,192,000,000                                                    
      acquisition of imago biosciences, inc., net of cash acquired
    		        0 0 -1,327,000,000                                                    
      payables to astrazeneca included in other noncurrent liabilities
    		          600,000,000                                                    
      cash flows from operating activities of continuing operations
    		                                                              
      net income from continuing operations
    		           3,018,000,000 3,252,000,000 3,949,000,000 4,307,000,000 3,824,000,000 4,571,000,000                                              
      adjustments to reconcile net income from continuing operations to net cash from operating activities of continuing operations:
    		                                                              
      charge for the acquisition of pandion therapeutics, inc.
    		               0 0                                              
      net cash from operating activities of continuing operations
    		           4,430,000,000 5,602,000,000 4,302,000,000 4,761,000,000                                                
      cash flows from investing activities of continuing operations
    		                                                              
      acquisition of acceleron pharma inc., net of cash acquired
    		                                                              
      acquisition of pandion therapeutics, inc., net of cash acquired
    		                                                              
      other acquisitions, net of cash acquired
    		           0    -90,000,000 1,000,000 -76,000,000 -14,000,000 -458,000,000 -586,000,000   -25,000,000 1,000,000                                      
      net cash from investing activities of continuing operations
    		           -1,748,000,000 -962,000,000 -1,077,000,000 -1,173,000,000                                                
      cash flows from financing activities of continuing operations
    		                                                              
      distribution from organon & co.
    		               0 0                                              
      net cash from financing activities of continuing operations
    		           -1,554,000,000 -2,702,000,000 -1,777,000,000 -3,086,000,000                                                
      cash flows from discontinued operations
    		                                                              
      net cash flows from discontinued operations
    		               -64,000,000 0                                              
      cash and cash equivalents
    		                                                              
      investments
    		                                                              
      identifiable intangible assets:
    		                                                              
      ipr&d - sotatercept
    		                                                              
      product rights - reblozyl
    		                                                              
      deferred income tax liabilities
    		                                                              
      loss (income) from investments in equity securities
    		           58,000,000 370,000,000 283,000,000 708,000,000                                                
      charge for the acquisition of velosbio inc.
    		                                                              
      purchase of seagen inc. common stock
    		                                                              
      acquisition of velosbio inc., net of cash acquired
    		                                                              
      acquisition of arqule, inc., net of cash acquired
    		                   0 0 0 -2,545,000,000                                        
      less: cash and cash equivalents related to discontinued operations
    		                                                              
      years ended december 31
    		                                                              
      sales
    		                                                              
      costs, expenses and other
    		                                                              
      restructuring costs
    		                                                              
      other income
    		                                                              
      income from discontinued operations before taxes
    		                                                              
      tax provision
    		                                                              
      income from discontinued operations, net of taxes
    		                                                              
      less: income of discontinued operations attributable to noncontrolling interests
    		                                                              
      income tax benefit
    		                                                              
      charge for the acquisition of peloton therapeutics, inc.
    		                                                              
      acquisition of antelliq corporation, net of cash acquired
    		                       0 0                                      
      acquisition of peloton therapeutics, inc., net of cash acquired
    		                       0                                       
      discontinued operations
    		                                                              
      adjustments to reconcile net income from continuing operations to net cash from operating activities:
    		                                                              
      net cash from operating activities from continuing operations
    		                4,797,000,000                                              
      acquisition of pandion therapeutics, inc. net of cash acquired
    		                0                                              
      net cash from investing activities from continuing operations
    		                -1,061,000,000                                              
      net cash from financing activities from continuing operations
    		                -2,274,000,000                                              
      charge for future payments related to collaboration license options
    		                           0                                   
      depreciation and amortization
    		                    852,000,000 1,048,000,000 821,000,000 936,000,000 845,000,000 973,000,000 898,000,000 1,095,000,000 1,061,000,000 1,226,000,000 1,137,000,000 1,128,000,000 1,154,000,000 1,162,000,000 1,193,000,000 1,155,000,000 1,175,000,000 1,550,000,000 1,561,000,000 1,560,000,000 1,570,000,000 1,608,000,000 1,637,000,000 1,573,000,000 1,611,000,000 1,753,000,000 1,754,000,000 1,954,000,000 1,705,000,000 1,861,000,000 1,903,000,000 1,832,000,000 1,831,000,000 1,866,000,000 1,879,900,000 1,947,700,000 1,687,400,000 296,000,000  394,000,000 543,000,000 876,000,000 
      charge for acquisition of peloton therapeutics, inc.
    		                                                              
      provisional charge for one-time transition tax related to the enactment of u.s. tax legislation
    		                                                              
      charge for collaboration termination
    		                                                              
      charge related to the settlement of worldwide keytruda patent litigation
    		                                                              
      acquisitions, net of cash acquired
    		                           -59,000,000                                   
      charge for future payments related to eisai collaboration license options
    		                             0 650,000,000                                
      acquisitions of businesses, net of cash acquired
    		                                0 -41,000,000 -306,000,000               0 0   -104,200,000 -10,500,000 -10,000,000 -131,300,000      
      charge for future payments related to astrazeneca collaboration license options
    		                               -250,000,000                               
      foreign currency devaluation related to venezuela
    		                                       161,000,000                       
      net charge related to the settlement of vioxx shareholder class action litigation
    		                                                              
      equity income from affiliates
    		                                   -27,000,000 -21,000,000 -4,000,000 -34,000,000 5,000,000 -63,000,000 -2,000,000 -145,000,000 -16,000,000 -24,000,000 -93,000,000 -124,000,000 -53,000,000 -102,000,000 -256,000,000 -161,000,000 -55,000,000 -138,000,000 -170,200,000 -236,400,000 -42,900,000 -137,500,000      
      dividends and distributions from equity method affiliates
    		                                                              
      acquisition of cubist pharmaceuticals, inc., net of cash acquired
    		                                       0 0 0 -7,598,000,000                    
      acquisitions of other businesses, net of cash acquired
    		                                   -2,000,000 -621,000,000 -10,000,000 -147,000,000 -36,000,000                       
      dispositions of businesses, net of cash divested
    		                                        126,000,000    490,000,000 25,000,000 533,000,000   0 0 17,000,000 306,000,000          
      effect of exchange rate changes on cash and cash equivalents
    		                               19,000,000 79,000,000 106,000,000 253,000,000 -484,000,000 53,000,000 156,000,000 144,000,000 -247,000,000 -85,000,000 -683,000,000 -295,000,000 -326,000,000 -278,000,000 18,000,000 33,000,000 -48,000,000 3,000,000 -40,000,000 -159,000,000 100,000,000 141,000,000 -210,700,000 47,100,000 104,200,000 -235,600,000      
      net increase in cash and cash equivalents
    		                               -1,809,000,000 115,000,000 -3,922,000,000 5,193,000,000 -1,392,000,000   1,192,000,000 976,000,000   539,000,000 -3,929,000,000 1,627,000,000 -6,085,000,000 207,000,000 1,531,000,000 -1,000,000,000 -722,000,000 1,911,000,000 647,000,000 795,000,000 1,026,000,000 1,208,800,000 429,600,000 -1,075,400,000   454,000,000   
      cash and cash equivalents at beginning of year
    		                               0 0 0 6,515,000,000 0 0 0 8,524,000,000 0 0 0 7,441,000,000 0 0 0 15,621,000,000 0 0 0 0 0 10,900,000,000 -400,000 0 0 9,311,400,000      
      cash and cash equivalents at end of year
    		                                                              
      cash and cash equivalents at end of period
    		                                115,000,000 -3,922,000,000 11,708,000,000  1,299,000,000 -3,108,000,000 9,716,000,000  626,000,000 -1,058,000,000 7,980,000,000  1,627,000,000 -6,085,000,000 15,828,000,000  -1,000,000,000  1,911,000,000 647,000,000 11,695,000,000  1,208,800,000 429,600,000 8,236,000,000      
      gain on divestiture of merck consumer care business
    		                                                              
      gain on astrazeneca option exercise
    		                                           0 0          0        
      loss on extinguishment of debt
    		                                                              
      divestiture of merck consumer care business, net of cash divested
    		                                                              
      dispositions of other businesses, net of cash divested
    		                                                              
      proceeds from astrazeneca option exercise
    		                                           0 0          0        
      acquisition of idenix pharmaceuticals, inc., net of cash acquired
    		                                           0                   
      acquisition of bayer ag collaboration rights
    		                                                              
      cash inflows from net investment hedges
    		                                                              
      other dividends paid
    		                                                              
      dividends and distributions from equity affiliates
    		                                    5,000,000 3,000,000 4,000,000  5,000,000 4,000,000 3,000,000  7,000,000 59,000,000 66,000,000 59,000,000 110,000,000 30,000,000 65,000,000 56,000,000 65,000,000 60,200,000 81,700,000 104,700,000 77,400,000      
      net decrease in cash and cash equivalents
    		                                                              
      foreign exchange losses related to venezuela
    		                                                              
      gain on divestiture of merck consumer care
    		                                                              
      divestiture of consumer care business, net of cash divested
    		                                                              
      gain on divestiture of certain ophthalmic products
    		                                                              
      gain on disposition of interest in equity method investment
    		                                                              
      proceeds from sale of interest in equity method investment
    		                                                              
      cash inflows (outflows) from net investment hedges
    		                                                              
      gain on astrazeneca lp asset option exercise
    		                                                              
      proceeds from astrazeneca lp asset option exercise
    		                                                              
      decrease in restricted assets
    		                                                              
      gain related to merck/schering-plough partnership
    		                                                              
      schering-plough merger, net of cash acquired
    		                                                              
      supplemental cash flow information
    		                                                              
      gain on astrazeneca asset option exercise
    		                                                              
      in-process research and development impairment charges
    		                                                    302,000,000          
      increase in restricted assets
    		                                                      200,000 18,100,000 -25,100,000      
      gains on distributions from astrazeneca lp
    		                                                              
      gain on disposition of interest in merial limited
    		                                                              
      proceeds from sale of interest in merial limited
    		                                                              
      distributions from astrazeneca lp
    		                                                              
      decrease (increase) in restricted assets
    		                                                              
      proceeds from the issuance of debt
    		                                                      0        
      net cash (used by) provided by investing activities
    		                                                        -3,148,100,000      
      net cash from (used by) financing activities
    		                                                        942,200,000      
      gain on distribution from astrazeneca lp
    		                                                              
      u.s. vioxx settlement agreement charge
    		                                                              
      in-process research and development
    		                                                              
      taxes paid for internal revenue service settlement
    		                                                              
      distribution from astrazeneca lp
    		                                                              
      net cash from (used by) investing activities
    		                                                              
      net cash used by financing activities
    		                                                              
      operating activities:
    		                                                              
      accrued share-based compensation
    		                                                         48,000,000  52,000,000 58,000,000 60,000,000 
      special, merger and acquisition-related charges and payments
    		                                                         -8,000,000     
      gain on sale of divested products
    		                                                              
      changes in assets and liabilities:
    		                                                              
      prepaid expenses and other assets
    		                                                         47,000,000 24,000,000 -8,000,000 -92,000,000 78,000,000 
      accounts payable
    		                                                         88,000,000  37,000,000   
      other liabilities
    		                                                         -189,000,000  -22,000,000   
      investing activities:
    		                                                              
      dispositions of property and equipment
    		                                                         1,000,000  2,000,000 4,000,000 27,000,000 
      contributions to benefit-related trusts
    		                                                              
      proceeds from divested products
    		                                                              
      purchases of short-term investments
    		                                                         -708,000,000     
      maturities of short-term investments
    		                                                         5,000,000  17,000,000 -15,000,000 25,000,000 
      financing activities:
    		                                                              
      payments of long-term debt
    		                                                         -71,000,000  -466,000,000   
      cash dividends paid to common shareholders
    		                                                         -106,000,000  -106,000,000 -106,000,000 -105,000,000 
      cash dividends paid to preferred shareholders
    		                                                         -38,000,000  -38,000,000 -37,000,000 -38,000,000 
      stock option exercises
    		                                                         36,000,000  11,000,000 2,000,000 2,000,000 
      effect of exchange rates on cash and cash equivalents
    		                                                         -42,000,000  -55,000,000 0 20,000,000 
      cash and cash equivalents, beginning of period
    		                                                         3,373,000,000 -1,788,000,000 0 0 2,279,000,000 
      cash and cash equivalents, end of period
    		                                                         2,845,000,000 -2,955,000,000 454,000,000 251,000,000 2,454,000,000 
      net (decrease)/increase in cash and cash equivalents
    		                                                              
      net (decrease) / increase in cash and cash equivalents
    		                                                         -528,000,000     
      income from operations
    		                                                              
      adjustments to reconcile income from operations to net cash from operating activities:
    		                                                              
      rebates payable
    		                                                              
      payable to merck and schering-plough
    		                                                              
      accrued expenses and other liabilities
    		                                                              
      non-cash charges
    		                                                              
      contributions from partners
    		                                                              
      distributions to partners
    		                                                              
      net increase/(decrease) in cash and cash equivalents
    		                                                             175,000,000 
      balance, january 1, 2006
    		                                                              
      balance, december 31, 2006
    		                                                              
      balance, december 31, 2007
    		                                                              
      balance, december 31, 2008
    		                                                              
      special and acquisition-related charges and payments
    		                                                           57,000,000   
      purchases of derivative instruments
    		                                                              
      change in fair value of foreign currency option
    		                                                              
      payments to u.s. taxing authorities
    		                                                              
      net cash (used for)/provided by investing activities
    		                                                           85,000,000 -206,000,000 -123,000,000 
      proceeds from preferred stock issuance
    		                                                              
      proceeds from common stock issuance
    		                                                              
      issuance of long-term debt
    		                                                              
      net cash (used for)/provided by financing activities
    		                                                              
      purchase of derivative currency option
    		                                                              
      accounts payable and other liabilities
    		                                                             -322,000,000 
      net cash provided by/(used for) operating activities
    		                                                             462,000,000 
      balance, january 1, 2005
    		                                                              
      balance, december 31, 2005
    		                                                              
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.